Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging strategies for cancer immunoprevention.

Literature DB >> 26364615

Emerging strategies for cancer immunoprevention.

Abstract

The crucial role of the immune system in the formation and progression of tumors has been widely accepted. On one hand, the surveillance role of the immune system plays an important role in endogenous tumor prevention, but on the other hand, in some special circumstances such as in chronic inflammation, the immune system can actually contribute to the formation and progression of tumors. In recent years, there has been an explosion of novel targeted immunotherapies for advanced cancers. In the present manuscript, we explore known and potential various types of cancer prevention strategies and focus on nonvaccine-based cancer preventive strategies targeting the immune system at the early stages of tumorigenesis.

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26364615 DOI： 10.1038/onc.2015.98

Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867

188 in total

1. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.

Authors: Stephanie K Watkins; Nejat K Egilmez; Jill Suttles; Robert D Stout
Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422

Review 2. Biologic effects of interferons.

Authors: I Gresser
Journal: J Invest Dermatol Date: 1990-12 Impact factor: 8.551

Review 3. Cancer immunoediting: from immunosurveillance to tumor escape.

Authors: Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal: Nat Immunol Date: 2002-11 Impact factor: 25.606

4. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

Authors: Bethany L Mundy-Bosse; Gregory S Young; Todd Bauer; Elaine Binkley; Mark Bloomston; Matthew A Bill; Tanios Bekaii-Saab; William E Carson; Gregory B Lesinski
Journal: Cancer Immunol Immunother Date: 2011-05-21 Impact factor: 6.968

5. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Authors: Anna Johansson; Stina Rudolfsson; Peter Hammarsten; Sofia Halin; Kristian Pietras; Jonathan Jones; Pär Stattin; Lars Egevad; Torvald Granfors; Pernilla Wikström; Anders Bergh
Journal: Am J Pathol Date: 2010-07-08 Impact factor: 4.307

Review 6. STAT3 as a central mediator of neoplastic cellular transformation.

Authors: David A Frank
Journal: Cancer Lett Date: 2006-11-28 Impact factor: 8.679

7. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.

Authors: Tim F Greten; Lars A Ormandy; Annika Fikuart; Bastian Höchst; Sylvana Henschen; Monique Hörning; Michael P Manns; Firouzeh Korangy
Journal: J Immunother Date: 2010 Feb-Mar Impact factor: 4.456

Emerging strategies for cancer immunoprevention.

1. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.

Review 2. Biologic effects of interferons.

Review 3. Cancer immunoediting: from immunosurveillance to tumor escape.

4. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.

5. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Review 6. STAT3 as a central mediator of neoplastic cellular transformation.

7. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.

8. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology.

9. Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice.

10. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival.

Review 1. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Review 2. Cancer Prevention: Lessons Learned and Future Directions.

3. Targets and Strategies for Cancer Immunoprevention.

Review 4. IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.

5. Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer.

6. Stat3 is indispensable for damage-induced crypt regeneration but not for Wnt-driven intestinal tumorigenesis.

Review 7. Highlighted STAT3 as a potential drug target for cancer therapy.

Review 8. Colorectal cancer prevention: Immune modulation taking the stage.

Review 9. Cancer immunoprevention: from mice to early clinical trials.

Review 10. Companion Animals as Models for Inhibition of STAT3 and STAT5.